---
schema_version: "secwatch.filing_event.v1"
accession: "0000914475-25-000120"
form_type: "8-K"
ticker: "NBIX"
cik: "0000914475"
company_name: "NEUROCRINE BIOSCIENCES INC"
filed_at: "2025-05-22T23:59:59+00:00"
generated_at: "2026-05-20T21:54:25.032208+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.2
confidence: "high"
source: SEC EDGAR
---

# Neurocrine holds 2025 annual meeting; shareholders approve new equity plan and amended ESPP

## Summary
- Four Class II directors elected for three-year terms expiring 2028: Kyle Gano, Richard Pops, Shalini Sharp, Stephen Sherwin (each >72M votes).
- Advisory say-on-pay approved: ~78M for, ~6M against, ~1.7M abstentions.
- 2025 Equity Incentive Plan approved: ~72.6M for, ~12.9M against.
- Amended and Restated 2018 ESPP approved: ~85.4M for, ~138K against.
- Ratification of Ernst & Young as independent auditor for FY2025 approved: ~85M for, ~5.2M against.

## SEC filing metadata
- accession: 0000914475-25-000120
- form_type: 8-K
- ticker: NBIX
- cik: 0000914475
- company_name: NEUROCRINE BIOSCIENCES INC
- filed_at: 2025-05-22T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.2
- confidence: high
- sec_items: 5.02, 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/914475/000091447525000120/0000914475-25-000120-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/914475/000091447525000120/nbix-20250521.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000914475-25-000120
- JSON: https://secwatch.observer/filing/0000914475-25-000120.json
- Plain text: https://secwatch.observer/filing/0000914475-25-000120.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.